choreatic disease
choreatic disease
Explore linked clinical trials. Standard reference: MONDO:000159571 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pridopidine Phase 3 Study in Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Recruiting | Phase 3 | 2026-10-07 | NCT07609108 | |
| Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers | Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Schizophrenia Spectrum and Other Psychotic Disorders, Signs and Symptoms, attention deficit hyperactivity disorder, inattentive type, central nervous system disorder, choreatic disease, movement disorder, nervous system disorder, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder, schizophrenia | Active, not recruiting | Not stated | 2026-10-02 | NCT00001246 | |
| A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Recruiting | Phase 3 | 2026-09-22 | NCT07326709 | |
| Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-21 | NCT07378644 | |
| Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers | Alzheimer disease, Arterial Occlusive Diseases, Chronic Disease, Cognition Disorders, Cognitive Dysfunction, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Creutzfeldt Jacob disease, Disease Attributes, Dyskinesias, Frontotemporal Lobar Degeneration, Huntington disease, Infections, Leukoencephalopathies, Lewy body dementia, Mixed Dementias, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, TDP-43 proteinopathy, arteriosclerosis disorder, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, central nervous system infectious disorder, cerebrovascular disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, intracranial arterial disease, intracranial arteriosclerosis, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, prion disease, proteostasis deficiencies, psychiatric disorder, synucleinopathy, tauopathy, vascular dementia, vascular disorder | Active, not recruiting | Not applicable | 2026-09-21 | NCT05596760 | |
| A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Recruiting | Phase 1 | 2026-09-16 | NCT06585449 | |
| A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Recruiting | Phase 1 | 2026-09-04 | NCT07536061 | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Active, not recruiting | Phase 1 | 2026-09-02 | NCT07246941 | |
| ScATtEred Rare Disease Biobanks: a Model of Sample/Data Collection With susTainablE and Shared Criteria | Abnormalities, Multiple, Bone Diseases, Developmental, Cardiovascular Abnormalities, Cognition Disorders, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Dyskinesias, Huntington disease, Hypersensitivity, Immediate, Marfan syndrome, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Rare Diseases, Skin and Connective Tissue Diseases, angioedema, basal ganglia disorder, bone disorder, brain disorder, cardiovascular disorder, central nervous system disorder, choreatic disease, cognitive disorder, congenital heart disease, connective tissue disorder, dementia, heart disorder, hereditary disease, immune system disorder, inherited neurodegenerative disorder, movement disorder, musculoskeletal system disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder, skin disorder, skin vascular disease, urticaria, vascular disorder | Recruiting | Not stated | 2026-08-27 | NCT06782230 | |
| A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, Machado-Joseph disease, Neurologic Manifestations, Spinocerebellar Ataxias, Spinocerebellar Degenerations, atactic disorder, non-human animal, basal ganglia disorder, brain disorder, central nervous system disorder, cerebellar ataxia, cerebellar disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder, spinal cord disorder, spinocerebellar ataxia type 1 | Recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT05822908 | |
| Digital Measures for Clinical Trial Endpoints in Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Recruiting | Not stated | 2026-08-17 | NCT07010705 | |
| Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study | Alzheimer disease, Arterial Occlusive Diseases, Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Frontotemporal Lobar Degeneration, Huntington disease, Leukoencephalopathies, Lewy body dementia, Neurologic Manifestations, Nutritional and Metabolic Diseases, Ocular Motility Disorders, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, amyotrophic lateral sclerosis, arteriosclerosis disorder, autonomic nervous system disorder, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, choreatic disease, cognitive disorder, corticobasal degeneration disorder, cranial nerve neuropathy, dementia, eye disorder, frontotemporal dementia, hereditary disease, inherited neurodegenerative disorder, intracranial arterial disease, intracranial arteriosclerosis, metabolic disease, motor neuron disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, neuromuscular disease, ophthalmoplegia, palsy, parkinsonian disorder, primary dysautonomia, progressive supranuclear palsy, proteostasis deficiencies, psychiatric disorder, spinal cord disorder, synucleinopathy, tauopathy, vascular dementia, vascular disorder | Active, not recruiting | Not stated | 2026-08-10 | NCT06209515 | |
| GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Active, not recruiting | Phase 2 | 2026-08-10 | NCT05686551 | |
| Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-05 | NCT04713982 | |
| An Extension of SKY-0515 in Participants With Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Enrolling by invitation | Phase 2 / Phase 3 | 2026-07-24 | NCT07537075 | |
| Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3) | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, Parkinson disease, anxiety disorder, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, psychiatric disorder, synucleinopathy | Active, not recruiting | Not applicable | 2026-07-20 | NCT07213648 | |
| Gait Analysis in Neurological Disease | Atypical Parkinson Disease, Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Gait Disorders, Neurologic, Gait, Frontal, Huntington disease, Neurologic Manifestations, Ocular Motility Disorders, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Spinocerebellar Ataxias, Spinocerebellar Degenerations, atactic disorder, non-human animal, autonomic nervous system disorder, autosomal dominant Parkinson disease 1, basal ganglia disorder, brain disorder, central nervous system disorder, cerebellar ataxia, cerebellar disorder, choreatic disease, cognitive disorder, corticobasal degeneration disorder, cranial nerve neuropathy, dementia, eye disorder, hereditary disease, inherited neurodegenerative disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, parkinsonian disorder, primary dysautonomia, progressive supranuclear palsy, psychiatric disorder, spinal cord disorder, synucleinopathy, tauopathy | Active, not recruiting | Not stated | 2026-07-08 | NCT02994719 | |
| Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Enrolling by invitation | Phase 3 | 2026-06-18 | NCT06312189 | |
| Neural Correlates of Movement Disorders Associated With PRRT2 Related Paroxysmal Kinesigenic Dyskinesia - an Ancillary Study of AMEDYST Research | Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, central nervous system disorder, choreatic disease, movement disorder, nervous system disorder | Recruiting | Not applicable | 2026-06-05 | NCT06701851 | |
| A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-05-14 | NCT05541627 | |
| A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Dyskinesias, Huntington disease, Neurologic Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Rare Diseases, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Recruiting | Phase 1 / Phase 2 | 2026-05-05 | NCT06826612 | |
| Longitudinal SV2A PET and MRI in Premanifest HD | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Active, not recruiting | Not applicable | 2026-05-05 | NCT06626412 | |
| Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-05-01 | NCT06873334 | |
| Longitudinal Assessment of Brain Structure and Function in Juvenile-onset Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, juvenile Huntington disease, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Active, not recruiting | Not stated | 2026-04-30 | NCT05707663 | |
| Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Recruiting | Not applicable | 2026-04-29 | NCT07513844 |